A Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010

An Open-label, Single-dose, Parallel-group Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010

This Study will evaluate the effects of renal function on pharmacokinetics and safety of DA-8010

Inclusion Criteria:

[Healthy Volunteer]

• Adult male or female, 19 years to 75 years
• eGFR ≥ 90 mL/min/1.73m^2
• Body weight over 45.0 kg and body mass index in the range of 18.0 to 40.0 kg/m^2
• The subjects signed and dated informed consent form after hearing a detailed explanation of the study, fully understanding and determined voluntarily to participate
• The subjects who are judged appropriate to participate this clinical trial according to the physical examination, laboratory examination and questionnaire

[Renal Impairment Patient]

• Adult male of female, 19 years to 75 years
• eGFR < 90 mL/min/1.73m^2, not on dialysis
• Body weight over 45.0 kg and body mass index in the range of 18.0 to 40.0kg/m^2
• The subjects signed and dated informed consent form after hearing a detailed explanation of the study, fully understanding and determined voluntarily to participate
• The subjects who are judged appropriate to participate this clinical trial according to the physical examination, laboratory examination and questionnaire

Exclusion Criteria:

• The subjects with acute illness
• The subjects with a history of gastrointestinal disease or surgery that may affect the absorption of Investigational Product
• The subjects hypersensitive to any of the Investigational Product components or other drug components
• The subjects who have continuously consumed excessive smoking or alcohol within 6 months of screening, or who cannot stop smoking, caffeine, or alcohol intake during hospitalization
• The subjects who have history of drug abuse
• The subjects who are pregnant or lactating
• The subjects who do not agree to exclude the possibility of pregnancy using the contraception from the date of the first administration of the Investigational Product until the 4 weeks after the last administration